Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights
Open accessThe DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a paradigmatic prevalent, long-lasting, and inflammatory skin condition with a diverse range of clinical manifestations. The etiology and clinical symptoms of AD are influenced by complex pathophysiological processes, which involve a strong genetic component, epidermal dysfunction, and immunological dysregulation, and a strong influence of other physiological and environmental factors. The FDA has approved targeted and well-tolerated immunomodulators including biologics like dupilumab and crisaborole, and small molecules such as baricitinib, as novel therapies for AD. They effectively treat AD but are too expensive for most patients. The review provides an update on the state of knowledge of AD pathogenesis, discusses the available diagnostic and scoring indices, and provides a scientific foundation for treatment methods for AD. This review also presents data on clinical efficacy of innovative treatments’ considering recent guidelines, emphasizing the newest medications and ongoing trials. Finally, the new implication of artificial intelligence (AI) in AD management is explored, where AI can speed up diagnosis and therapy. The PubMed, Google Scholar, and ScienceDirect databases were used for this review. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Airborne particles degrade the skin barrier and increase IL-4/IL13 mediated inflammation and may also alter the cutaneous microbiome, further aggravating AD [65].”
From The Environmental Determinants of Skin Health: Linking Climate Change, Air Pollution, and the Dermatologic Disease Burden (2025) · cites this paper as [65]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hashimoto, D., Chow, A., Noizat, C., Teo, P., Beasley, M. B., Leboeuf, M., Becker, C. D., See, P., Price, J., Lucas, D., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.004 · Cited by 2,311 · cited 1×
“Monocytes are precursors of macrophages, which are highly mobile phagocytic cells capable of initiating immune responses (Hashimoto et al. 2013).”
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“SOLO 1 and SOLO 2 clinical studies involved enrolling individuals with moderate-to-severe atopic dermatitis whose condition was not well controlled by topical therapy in two randomized, placebo-controlled, phase 3 studies of the same design (Simpson et al. 2016).”
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Kunz, B., Oranje, A. P., Labrèze, L., Stalder, J.-F., Ring, J., & Taïeb, A. (1997) · Dermatology · doi:10.1159/000245677 · Cited by 1,046
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Skin pH: from basic science to basic skin care
Ali, S., & Yosipovitch, G. (2013) · Acta Dermato Venereologica · doi:10.2340/00015555-1531 · Cited by 690
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Staphylococcus δ-toxin induces allergic skin disease by activating mast cells
Nakamura, Y., Oscherwitz, J., Cease, K. B., Chan, S. M., Muñoz-Planillo, R., Hasegawa, M., Villaruz, A. E., Cheung, G. Y. C., McGavin, M. J., Travers, J. B., et al. (2013) · Nature · doi:10.1038/nature12655 · Cited by 558 · cited 1×
“Additionally, through Toll-like receptor 2 (TLR2), S. aureus induces thymic stromal lymphopoietin production and mast cell degranulation (Nakamura et al. 2013).”
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3023 · Cited by 516 · cited 2×
“Similarly, other studies showed clinically significant improvements in all primary and secondary objectives (Blauvelt et al. 2021; Silverberg et al. 2023b).”
Skin lesion segmentation in dermoscopy images via deep full resolution convolutional networks
Al-masni, M. A., Al-antari, M. A., Choi, M.-T., Han, S.-M., & Kim, T.-S. (2018) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2018.05.027 · Cited by 483
Cited by
Abdel-Mageed, H. M. (2025) · Micro and Nano Systems Letters · doi:10.1186/s40486-025-00228-2 · Cited by 67
Self-citationAtopic Dermatitis and Climate: Environmental Stressors and Care Strategies
Russo, F., Zink, A., Magnolo, N., Scala, E., & Scala, E. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01560-6 · Cited by 15
The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy
Zhang, Z., Chang, C., Xiao, L., Su, H., Lyu, Y., Zhao, J., Chen, J., Gou, K., Zhou, J., Wang, C., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s578036 · Cited by 15
Athavale, T., Nalliah, M., Obuobi, S. A. O., Grimstad, Ø., & Škalko‐Basnet, N. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103876 · Cited by 14
Zieneldien, T., Ma, S., Tan, I. J., Kim, J., Busot, D., & Cohen, B. A. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22121820 · Cited by 7
Metadata
- Authors
- Abdel-Mageed, H. M.
- Affiliations
- National Research Centre (EG)
- Corresponding author
- Abdel-Mageed, Heidi M.
- Venue
- Inflammopharmacology
- Published
- 2025-02-07
- Volume
- 33
- Issue
- 3
- Pages
- 1161-1187
- ISSN
- 0925-4692 (ISSN-L)
- 1568-5608
- PMC
- PMC11914373
- OpenAlex
- W4407260598
- Cited by
- 45
- References
- 160
- Citations by year
- 2026: 28 · 2025: 17
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Inflammopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Research Centre Egypt
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, pathogenesis, genetic susceptibility, immune dysregulation, dupilumab, crisaborole, baricitinib, biologics, small molecule therapy, treatment efficacy, artificial intelligence in dermatology, treatment costs
- MeSH terms
- Animals, Artificial Intelligence, Dermatitis, Atopic, Humans, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights. https://app.cochat.ai/papers/10.1007/s10787-025-01642-z
- The paper
- Abdel-Mageed, H. M. (2025). Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01642-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.